MaxCyte | Investor Presentation Deck | 19 slides · page 9 of 19
The slide highlights the transition from RUO to cGMP capabilities across the product line.
Pitch deck · solution · present_solution · dense density
Slide locked Sign in to view
Slide schematic 4/4
image 1/1 list 2/2 title 1/1
Components 4
illustration bullet bullet headline
Tools 2
Audience Definition slide · 70%
The ExPERT™ Platform Enabling Non-Viral Cell Engineering, targeted at customers in the cell therapy and drug discovery markets.
Value Proposition Canvas slide · 60%Enabling customers to use... Agnostic to cell type... High Performance: >90% transfection efficiencies, >90% cell viabilities
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.